European Respiratory Journal

Papers
(The H4-Index of European Respiratory Journal is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
The right ventricle tamed1059
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis793
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?667
Chymase-1: a “MAST”-er switch in COPD?344
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence234
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease212
Missing airways, ventilation defects and conductive airway physiology in asthma201
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe175
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow164
A breath of the future: a novel human model for COPD and beyond147
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?145
The lung that rules the heart145
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?133
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD131
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis128
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan125
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?123
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al121
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet115
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)115
Combining rituximab with mycophenolate for the treatment of interstitial lung disease109
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD107
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study97
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial97
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection96
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD93
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections93
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey90
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea88
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms84
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis84
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis83
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target82
Treatment algorithm for pulmonary arterial hypertension82
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?81
The environmental impact of inhaled therapy: making informed treatment choices81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study81
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor81
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis80
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era78
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation78
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume78
The association between immunosuppressants and outcomes of COVID-1977
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?77
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?76
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis76
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis75
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis74
Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension74
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study74
The limits of normal of pulmonary arterial wedge pressure73
Reply: Tuberculosis screening in migrants to the EU/EEA and UK72
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?72
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough72
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines71
Screening asymptomaticBMPR2mutation carriers: a new frontier for pulmonary hypertension physicians?69
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis66
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?63
Pleural mesothelioma: surgery questioned again?63
List ofEuropean Respiratory Journalpeer reviewers 202361
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?60
0.095095157623291